USMLE

Erlotinib

4,037 views
Oncology Pharm
  1. Bleomycin
  2. Dactinomycin, Actinomycin D
  3. Doxorubicin, Daunorubicin
  4. Azathioprine, 6-MP
  5. Cladribine
  6. Cytarabine
  7. Busulfan
  8. Cyclophosphamide, Ifosfamide
  9. Nitrosoureas
  10. Paclitaxel
  11. Vincristine, Vinblastine
  12. Cisplatin, Carboplatin, Oxaliplatin
  13. Etoposide, Teniposide
  14. Irinotecan, Topotecan
  15. Bevacizumab
  16. Erlotinib
  17. Cetuximab, Panitumumab
  18. Imatinib, Dasatinib
  19. Rituximab
  20. Bortezomib, Carfilzomib
  21. Trastuzumab
  22. Dabrafenib, Vemurafenib
  23. Raloxifene and Tamoxifen
  24. Hydroxyurea
  25. Procarbazine

Summary

Erlotinib is an EGFR tyrosine kinase inhibitor. It’s used to treat advanced, non-small cell lung cancer with an EGFR mutation. An adverse side effect of Erlotinib is the development of rashes on the face and back.

Key Points

  • Erlotinib
    • Mechanism
      • EGFR tyrosine kinase inhibitor
    • Clinical use
      • Non-small cell lung cancer
        • Advanced Non-small cell lung cancer with an EGFR mutation 
    • Adverse effects
      • Rash (nonspecific)